Collectively, our findings support an oncogenic role of DLGAP1-AS2 in GC progression and suggest that DLGAP1-AS2/Six3/Wnt1/β-catenin signaling axis may be a potential target for diagnosis and treatment of GC. Here, SIX3 is linked to gastric cancer.